Month: September 2013

ATHENS, Greece (AP) — A Greek aid group says suicides have increased by 45 percent during the first four years of Greece's financial crisis, and warned there are indications of a further "very large rise" in the past two years.

DURHAM, N.C. (AP) — Before Atkins, South Beach and Paleo, there was the Rice Diet.

WASHINGTON (AP) — A new report says the U.S. is facing a crisis in cancer care in a time of aging baby boomers, complex new treatments and rising costs.

(Updates with ECA comments, changes dateline) By Brian Homewood GENEVA, Sept 10 (Reuters) – European soccer clubs want to be involved in discussions over a possible winter World Cup in Qatar in 2022 and have urged FIFA not to rush a decision, saying there is “no hurry”. Soccer’s governing body FIFA will meet next month to discuss a proposal from president Sepp Blatter to shift the finals to the northern-hemisphere winter because of the searing heat in Qatar in the summer. …

LONDON (Reuters) – The UK anti-fraud agency seeking to prosecute Japan's Olympus Corp for misleading an auditor needs first to clarify whether a company can commit certain offences under UK law, a London court heard on Tuesday. Britain's Serious Fraud Office (SFO) last week brought five charges against the endoscope-to-camera maker and Gyrus, its UK medical equipment subsidiary, which have battled to restore a reputation decimated by a $1.7 billion (1 billion pounds) accounting scandal. …

(Reuters) – Trial data on Swiss drugmaker Roche’s breast cancer treatment Perjeta supported a faster approval of the drug for use in early stages of the disease, reviewers for the U.S. Food and Drug Administration said on Tuesday. Roche is seeking approval for Perjeta as a neoadjuvant, or initial, treatment for early stage breast cancer patients whose cancer cells contain increased amounts of the HER2 protein. A neoadjuvant treatment is given in the beginning to shrink a tumor before the main treatment. …

WASHINGTON (AP) — The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option for treating the earliest stages of the disease.